国产减肥药加速突围:如何与进口药竞争?是否还有BD预期?

澎湃新闻
Aug 12

继仁会生物的贝那鲁肽之后,减肥药这一黄金赛道又迎来了国产创新选手。8月10日,信达生物(1801.HK)在2025体重管理产业会议宣布,其胰高血糖素(GCG) /胰高血糖素样肽-1(GLP-1) 双受体激动剂玛仕度肽注射液(商品名:信尔美)正式全渠道上市。此前的6月27日,玛仕度肽在国内获批用于成人肥胖或超重患者的长期体重控制,成为全球首个GCG/GLP-1双受体激动减重药物。据信达生物公布的研究...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10